Business intelligence reports for the lab diagnostics industry
Subscribe for Exclusive Access.
Subscriptions & Reports
![Mar2022-DTET-Cover](https://g2woo.wpengine.com/wp-content/uploads/2022/03/Mar2022-DTET-Cover.webp)
![March2022-LCA.Cover](https://g2woo.wpengine.com/wp-content/uploads/2022/03/March2022-LCA.Cover_.webp)
![March2022-LIR-Cover](https://g2woo.wpengine.com/wp-content/uploads/2022/03/March2022-LIR-Cover.webp)
![April-2022-NLR-Briefing-Cover](https://g2woo.wpengine.com/wp-content/uploads/2022/03/April-2022-NLR-Briefing-Cover.webp)
Interested in multiple copies or more than one of our G2 reports?
Call Sokha at 855-528-6903 or email spearson@g2intelligence.com to discuss pricing.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
No Results Found
The posts you requested could not be found. Try changing your module settings or create some new posts.
Shift to Gene Panels to Assess Hereditary Cancer Risk Forges Ahead
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies A virtually unlimited number of genes tied to hereditary cancer risk can be simultaneously assessed in commercially available tests given both advances in technology and the Supreme Court's...
Two FDA Workshops Focus on Precision Medicine Issues
By Kelly A. Briganti, Editorial Director, G2 Intelligence Building on discussions started in February this year, the FDA has announced two workshops it will be holding this fall regarding next-generation sequencing standards and use of databases to establish...
Trovagene Develops Urine-Based Liquid Biopsy Test for Lung Cancer Patients
By Ron Shinkman, Editor, Laboratory Industry Report San Diego-based genomic laboratory Trovagene is developing an unconventional approach to liquid biopsies for lung cancer patients, relying on specimens of urine rather than blood. According to Trovagene's...
Air Force Expands Longitudinal Genomics Study
By Lori Solomon, Editor, Diagnostic Testing & Emerging Technologies The Air Force Medical Service (AFMS) in partnership with the Coriell Institute for Medical Research (Camden, N.J.) have launched phase II of the longitudinal Clinical Utility Study (CUS). CUS...